AAAAAA

   
Results: 1-13 |
Results: 13
EPIRUBICIN (EPI) AND TAXOTERE (TXT) AS FIRST LINE CHEMOTHERAPY IN ADVANCED BREAST-CANCER - A PHASE-I STUDY
Authors: MICHELOTTI A VENTURINI M PAPALDO P DONATI S DELMASTRO L GARRONE O BERGAGLIO M LIONETTO R GUELFI M SGUOTTI C COGNETTI F ROSSO R CONTE PF
Citation: A. Michelotti et al., EPIRUBICIN (EPI) AND TAXOTERE (TXT) AS FIRST LINE CHEMOTHERAPY IN ADVANCED BREAST-CANCER - A PHASE-I STUDY, Annals of oncology, 9, 1998, pp. 85-85
AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) IN FIRST REMISSION IMPROVES OUTCOME IN ADULT PATIENTS (PTS) WITH LYMPHOBLASTIC LYMPHOMA (LBL) -RESULTS FROM A RANDOMIZED TRIAL OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (EBMT) AND THE UK LYMPHOMA GROUP (UKLG)
Authors: SANTINI G SWEETENHAM JW SIMNETT S GUELFI M BRUZZI P PARMAR M QIAN W NAGLER A HOLTE H GOLDSTONE AH
Citation: G. Santini et al., AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) IN FIRST REMISSION IMPROVES OUTCOME IN ADULT PATIENTS (PTS) WITH LYMPHOBLASTIC LYMPHOMA (LBL) -RESULTS FROM A RANDOMIZED TRIAL OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (EBMT) AND THE UK LYMPHOMA GROUP (UKLG), Bone marrow transplantation, 21, 1998, pp. 624-624
PHARMACOKINETICS OF THE BICYCLIC PEPTIDE TACHYKININ NK2 RECEPTOR ANTAGONIST MEN-11420 (NEPADUTANT) IN RATS
Authors: LIPPI A CRISCUOLI M GUELFI M SANTICIOLI P MAGGI CA
Citation: A. Lippi et al., PHARMACOKINETICS OF THE BICYCLIC PEPTIDE TACHYKININ NK2 RECEPTOR ANTAGONIST MEN-11420 (NEPADUTANT) IN RATS, Drug metabolism and disposition, 26(11), 1998, pp. 1077-1081
[H-3]MEN-11420 - A NOVEL LIGAND FOR THE SELECTIVE LABELING OF TACHYKININ NK2 RECEPTORS
Authors: CRISCUOLI M RENZETTI AR CUCCHI P GUELFI M MAGGI CA
Citation: M. Criscuoli et al., [H-3]MEN-11420 - A NOVEL LIGAND FOR THE SELECTIVE LABELING OF TACHYKININ NK2 RECEPTORS, Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 1627-1627
CHARACTERIZATION OF [H-3]MEN-11420, A NOVEL GLYCOSYLATED PEPTIDE ANTAGONIST RADIOLIGAND OF THE TACHYKININ NK2 RECEPTOR
Authors: RENZETTI AR CATALIOTO RM CRISCUOLI M CUCCHI P LIPPI A GUELFI M QUARTARA L MAGGI CA
Citation: Ar. Renzetti et al., CHARACTERIZATION OF [H-3]MEN-11420, A NOVEL GLYCOSYLATED PEPTIDE ANTAGONIST RADIOLIGAND OF THE TACHYKININ NK2 RECEPTOR, Biochemical and biophysical research communications (Print), 248(1), 1998, pp. 78-82
EFFECT OF ADJUVANT CHEMOTHERAPY WITH OR WITHOUT ANTHRACYCLINES ON THEACTIVITY AND EFFICACY OF FIRST-LINE CYCLOPHOSPHAMIDE, EPIDOXORUBICIN,AND FLUOROURACIL IN PATIENTS WITH METASTATIC BREAST-CANCER
Authors: VENTURINI M BRUZZI P DELMASTRO L GARRONE O BERTELLI G GUELFI M PASTORINO S ROSSO R SERTOLI MR
Citation: M. Venturini et al., EFFECT OF ADJUVANT CHEMOTHERAPY WITH OR WITHOUT ANTHRACYCLINES ON THEACTIVITY AND EFFICACY OF FIRST-LINE CYCLOPHOSPHAMIDE, EPIDOXORUBICIN,AND FLUOROURACIL IN PATIENTS WITH METASTATIC BREAST-CANCER, Journal of clinical oncology, 14(3), 1996, pp. 764-773
MULTICENTER RANDOMIZED CONTROLLED CLINICAL-TRIAL TO EVALUATE CARDIOPROTECTION OF DEXRAZOXANE VERSUS NO CARDIOPROTECTION IN WOMEN RECEIVING EPIRUBICIN CHEMOTHERAPY FOR ADVANCED BREAST-CANCER
Authors: VENTURINI M MICHELOTTI A DELMASTRO L GALLO L CAMINO F GARRONE O TIBALDI C MOLEA N BELLINA RC PRONZATO P CYRUS P VINKE J TESTORE F GUELFI M LIONETTO R BRUZZI P CONTE PF ROSSO R
Citation: M. Venturini et al., MULTICENTER RANDOMIZED CONTROLLED CLINICAL-TRIAL TO EVALUATE CARDIOPROTECTION OF DEXRAZOXANE VERSUS NO CARDIOPROTECTION IN WOMEN RECEIVING EPIRUBICIN CHEMOTHERAPY FOR ADVANCED BREAST-CANCER, Journal of clinical oncology, 14(12), 1996, pp. 3112-3120
CONVENTIONAL-DOSE VERSUS HIGH BOSE POSTREMISSION THERAPY FOR ADULTS WITH LYMPHOBLASTIC LYMPHOMA - A PROGRESS REPORT ON THE EBMT UKLG TRIAL ARID A PRELIMINARY-ANALYSIS OF PROGNOSTIC FACTORS/
Authors: SWEETENHAM JW SANTINI G SIMNETT S GIBSON D GUELFI M BRUZZI P MACHIN D GOLDSTONE AH
Citation: Jw. Sweetenham et al., CONVENTIONAL-DOSE VERSUS HIGH BOSE POSTREMISSION THERAPY FOR ADULTS WITH LYMPHOBLASTIC LYMPHOMA - A PROGRESS REPORT ON THE EBMT UKLG TRIAL ARID A PRELIMINARY-ANALYSIS OF PROGNOSTIC FACTORS/, Blood, 88(10), 1996, pp. 484-484
PHARMACOLOGY OF LR-B 057, A NOVEL ORALLY-ACTIVE AT(1) RECEPTOR ANTAGONIST/
Authors: RENZETTI AR CUCCHI P GUELFI M CIRILLO R SALIMBENI A SUBISSI A GIACHETTI A
Citation: Ar. Renzetti et al., PHARMACOLOGY OF LR-B 057, A NOVEL ORALLY-ACTIVE AT(1) RECEPTOR ANTAGONIST/, Journal of cardiovascular pharmacology, 25(3), 1995, pp. 354-360
PHARMACOLOGY OF LR-B 081, A NEW HIGHLY POTENT, SELECTIVE AND ORALLY-ACTIVE, NONPEPTIDE ANGIOTENSIN-II AT(1) RECEPTOR ANTAGONIST/
Authors: CIRILLO R RENZETTI AR CUCCHI P GUELFI M SALIMBENI A CALIARI S CASTELLUCCI A EVANGELISTA S SUBISSI A GIACHETTI A
Citation: R. Cirillo et al., PHARMACOLOGY OF LR-B 081, A NEW HIGHLY POTENT, SELECTIVE AND ORALLY-ACTIVE, NONPEPTIDE ANGIOTENSIN-II AT(1) RECEPTOR ANTAGONIST/, British Journal of Pharmacology, 114(6), 1995, pp. 1117-1124
MATERNAL UNIPARENTAL DISOMY FOR CHROMOSOME-14
Authors: COVIELLO DA PANUCCI E MANTEROL MM PERFUMOL C GUELFI M BORRONEO C DAGNABRICARELLI F
Citation: Da. Coviello et al., MATERNAL UNIPARENTAL DISOMY FOR CHROMOSOME-14, American journal of human genetics, 57(4), 1995, pp. 617-617
TRIAXIAL EXPOSURE SYSTEM PROVIDING STATIC AND LOW-FREQUENCY MAGNETIC-FIELDS FOR IN-VIVO AND IN-VITRO BIOLOGICAL STUDIES
Authors: RAGANELLA L GUELFI M DINZEO G
Citation: L. Raganella et al., TRIAXIAL EXPOSURE SYSTEM PROVIDING STATIC AND LOW-FREQUENCY MAGNETIC-FIELDS FOR IN-VIVO AND IN-VITRO BIOLOGICAL STUDIES, Bioelectrochemistry and bioenergetics, 35(1-2), 1994, pp. 121-126
LR-B 057 - A NOVEL ORALLY-ACTIVE AT1 RECEPTOR ANTAGONIST/
Authors: RENZETTI AR CUCCHI P GUELFI M SALIMBENI A SUBISSI A
Citation: Ar. Renzetti et al., LR-B 057 - A NOVEL ORALLY-ACTIVE AT1 RECEPTOR ANTAGONIST/, British Journal of Pharmacology, 111, 1994, pp. 160000267-160000267
Risultati: 1-13 |